

Title (en)  
2,5-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE

Title (de)  
2,5 SUBSTITUIERTE ARYL PYRROL, DIESES ENTHALTENDE ZUSAMMENSETZUNGEN UND DESSEN VERWENDUNG

Title (fr)  
PYRROLES D'ARYLE SUBSTITUES EN POSITION 2 ET 5, COMPOSITIONS CONTENANT DE TELS COMPOSES ET LEURS MODES D'UTILISATION

Publication  
**EP 0871444 A1 19981021 (EN)**

Application  
**EP 96928099 A 19960806**

Priority

- GB 9607253 A 19960404
- GB 9608472 A 19960425
- US 9612922 W 19960806
- US 209495 P 19950810
- US 1418296 P 19960326

Abstract (en)  
[origin: WO9705878A1] The present invention addresses 2,5-substituted aryl pyrroles of formula (I); or pharmaceutically acceptable salts thereof, as well as compositions containing such compounds and methods of treatment. The compounds are useful for treating Cytokine mediated diseases, which refers to diseases or conditions in which excessive or unregulated production or activity of one or more cytokines occurs. Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8) and Tumor Necrosis Factor (TNF) are cytokines which are involved in immunoregulation and other physiological conditions, such as inflammation. The compounds also have glucagon antagonist activity.

IPC 1-7  
**A61K 31/44**; **A61K 31/50**; **A61K 31/445**; **A61K 31/495**; **A61K 31/505**; **A61K 31/535**; **C07D 211/68**; **C07D 211/80**; **C07D 213/02**; **C07D 239/02**; **C07D 401/00**

IPC 8 full level  
**A61K 31/00** (2006.01); **A61K 31/44** (2006.01); **A61K 31/4427** (2006.01); **A61K 31/443** (2006.01); **A61K 31/4433** (2006.01); **A61K 31/4439** (2006.01); **A61K 31/445** (2006.01); **A61K 31/4465** (2006.01); **A61K 31/4523** (2006.01); **A61K 31/4545** (2006.01); **A61K 31/47** (2006.01); **A61K 31/4709** (2006.01); **A61K 31/495** (2006.01); **A61K 31/496** (2006.01); **A61K 31/505** (2006.01); **A61K 31/506** (2006.01); **A61K 31/535** (2006.01); **A61K 31/5375** (2006.01); **A61K 31/5377** (2006.01); **A61P 1/00** (2006.01); **A61P 1/04** (2006.01); **A61P 9/00** (2006.01); **A61P 19/00** (2006.01); **A61P 29/00** (2006.01); **A61P 31/00** (2006.01); **A61P 37/00** (2006.01); **A61P 43/00** (2006.01); **C07D 401/04** (2006.01); **C07D 401/14** (2006.01); **C07D 403/04** (2006.01); **C07D 405/14** (2006.01); **C07D 409/14** (2006.01); **C07D 413/14** (2006.01); **C07D 471/04** (2006.01)

CPC (source: EP)  
**A61P 1/00** (2017.12); **A61P 1/04** (2017.12); **A61P 9/00** (2017.12); **A61P 19/00** (2017.12); **A61P 29/00** (2017.12); **A61P 31/00** (2017.12); **A61P 37/00** (2017.12); **A61P 43/00** (2017.12); **C07D 401/04** (2013.01); **C07D 401/14** (2013.01); **C07D 403/04** (2013.01); **C07D 471/04** (2013.01)

Designated contracting state (EPC)  
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)  
**WO 9705878 A1 19970220**; AU 6769196 A 19970305; AU 699148 B2 19981126; CA 2228050 A1 19970220; EP 0871444 A1 19981021; EP 0871444 A4 19990113; JP H11510511 A 19990914

DOCDB simple family (application)  
**US 9612922 W 19960806**; AU 6769196 A 19960806; CA 2228050 A 19960806; EP 96928099 A 19960806; JP 50866197 A 19960806